Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MRNS

Marinus Pharmaceuticals Inc

Apr 16 • 02:39PM ET

1.18

Dollar change -0.12
Percentage change -9.15	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO IWM IWO IBB VTWG VFMO SURI IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.63	Insider Own	7.01%	Shs Outstand	54.58M	Perf Week	-85.91%
Market Cap	64.53M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	-0.57%	Shs Float	50.81M	Perf Month	-87.42%
Income	-141.41M	PEG	-	EPS next Q	-0.66	Inst Own	94.03%	Short Float	6.84%	Perf Quarter	-87.61%
Sales	30.99M	P/S	2.08	EPS this Y	16.40%	Inst Trans	1.35%	Short Ratio	3.47	Perf Half Y	-82.83%
Book/sh	0.31	P/B	3.84	EPS next Y	36.24%	ROA	-65.70%	Short Interest	3.47M	Perf Year	-84.02%
Cash/sh	2.75	P/C	0.43	EPS next 5Y	20.00%	ROE	-213.02%	52W Range	1.25 - 11.26	Perf YTD	-89.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.04%	ROI	-125.60%	52W High	-89.51%	Beta	1.12
Dividend TTM	-	Quick Ratio	4.01	Sales past 5Y	176.17%	Gross Margin	91.51%	52W Low	-5.52%	ATR (14)	0.94
Dividend Ex-Date	-	Current Ratio	4.07	EPS Y/Y TTM	-520.26%	Oper. Margin	-424.30%	RSI (14)	11.11	Volatility	15.74% 8.96%
Employees	165	Debt/Eq	6.58	Sales Y/Y TTM	21.63%	Profit Margin	-456.31%	Recom	1.55	Target Price	10.44
Option/Short	Yes / Yes	LT Debt/Eq	5.71	EPS Q/Q	3.42%	Payout	-	Rel Volume	20.20	Prev Close	1.30
Sales Surprise	-10.18%	EPS Surprise	-18.74%	Sales Q/Q	0.39%	Earnings	Mar 05 AMC	Avg Volume	1.00M	Price	1.18
SMA20	-85.70%	SMA50	-87.00%	SMA200	-86.06%	Trades		Volume	16,236,427	Change	-9.15%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	Robert W. Baird	Outperform → Neutral	$20 → $2
Apr-15-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $3
Aug-11-23	Downgrade	Oppenheimer	Outperform → Perform	$14 → $9
Jan-20-23	Initiated	RBC Capital Mkts	Outperform	$23
Sep-30-20	Initiated	Truist	Buy	$35
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$6 → $9
Jul-01-20	Initiated	Cowen	Outperform
Apr-09-20	Initiated	Craig Hallum	Buy	$4.50
Dec-20-19	Initiated	Oppenheimer	Outperform
Mar-05-19	Resumed	Jefferies	Buy	$3.50 → $10
Feb-27-19	Downgrade	Mizuho	Buy → Neutral	$13 → $5
Feb-06-19	Initiated	Leerink Partners	Outperform	$10
Jul-02-18	Initiated	Cantor Fitzgerald	Overweight	$19
Mar-20-18	Initiated	Mizuho	Buy	$13
Feb-15-18	Initiated	H.C. Wainwright	Buy	$33
Dec-14-17	Initiated	Laidlaw	Buy	$18
Aug-10-16	Reiterated	Jefferies	Buy	$2.50 → $3
Jun-14-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-08-16	Reiterated	Stifel	Buy	$23 → $16
Dec-17-15	Initiated	RBC Capital Mkts	Outperform	$14

Show Previous Ratings

Today 11:46AM	Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study (Zacks) -9.15%
Apr-15-24 11:30AM	Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today? (InvestorPlace) -82.71%
07:00AM	Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results (Business Wire)
Apr-05-24 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -10.14%
Mar-27-24 08:41AM	Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review (Business Wire)
10:00AM	Loading…
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 10:32AM	Do Options Traders Know Something About Marinus (MRNS) Stock We Don't? (Zacks)
Mar-07-24 01:41PM	Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
11:10AM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 07:14AM	Q4 2023 Marinus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 05:10PM	Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:24PM	Marinus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-21-24 07:00AM	Marinus Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Feb-20-24 07:00AM	Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (Business Wire)
04:00PM	Loading…
Feb-16-24 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-30-24 08:13PM	Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment (TipRanks)
Jan-22-24 09:56AM	Should You Add Marinus (MRNS) Stock to Your Portfolio Now? (Zacks) +5.31%
Jan-17-24 09:55AM	Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a Bet (Zacks)
Jan-04-24 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
07:01AM	Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update (Business Wire)
Dec-29-23 06:45AM	5 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-07-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Nov-20-23 04:01PM	Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study (Business Wire)
Nov-14-23 04:05PM	Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-09-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -14.07%
Nov-08-23 04:32PM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.91%
Nov-07-23 07:55AM	Marinus Pharmaceuticals Inc (MRNS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:36AM	Marinus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results (Business Wire)
07:00AM	Loading…
07:00AM	Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY (ganaxolone) Oral Suspension CV (Business Wire)
Oct-24-23 07:01AM	Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-11-23 09:55AM	Wall Street Analysts Believe Marinus Pharmaceuticals (MRNS) Could Rally 183.33%: Here's is How to Trade (Zacks)
Oct-06-23 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Sep-21-23 04:00PM	Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference (Business Wire) -6.18%
Sep-20-23 09:02AM	Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock? (Zacks)
09:01AM	Marinus (MRNS) Up 20% on Financial and Pipeline Updates (Zacks)
Sep-19-23 04:51PM	Marinus Pharmaceuticals extends cash runway, shares surge 16% (Investing.com) +19.88%
08:00AM	Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event (Business Wire)
Sep-12-23 04:00PM	Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 (Business Wire)
Sep-06-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-17-23 04:01PM	Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 (Business Wire)
Aug-11-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -13.56%
09:36AM	Twilio upgraded, Sealed Air downgraded: Wall Street's top analyst calls (The Fly)
Aug-10-23 08:40AM	Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.10%
07:34AM	Marinus Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:01AM	Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 12:03PM	Marinus secures European Commission approval for Ztalmy (American City Business Journals) +5.03%
07:01AM	Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder (Business Wire)
Jul-27-23 07:01AM	Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023 (Business Wire)
Jul-25-23 03:48PM	Marinus Pharmaceuticals (NASDAQ:MRNS) shareholders have earned a 71% return over the last year (Simply Wall St.)
Jul-13-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-03-23 04:23AM	Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jun-21-23 04:01PM	Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus (Business Wire)
Jun-12-23 07:59AM	Institutional investors are Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) biggest bettors and were rewarded after last week's US$149m market cap gain (Simply Wall St.)
Jun-02-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
May-26-23 08:10AM	Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder (Business Wire)
May-17-23 04:01PM	Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D. (Business Wire)
May-16-23 11:50AM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2023 Earnings Call Transcript (Insider Monkey)
06:01AM	Analyst Forecasts For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher (Simply Wall St.)
May-11-23 08:35AM	Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:24AM	Marinus Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
07:01AM	Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results (Business Wire)
May-09-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
May-04-23 10:00AM	Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline (Zacks)
May-03-23 07:01AM	Marinus Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Apr-27-23 07:01AM	Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-18-23 11:03AM	Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price Matching Investor Opinion (Simply Wall St.)
07:01AM	Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors (Business Wire)
04:30AM	Marinus Pharmaceuticals (MRNS) Stock Jumps 8.4%: Will It Continue to Soar? (Zacks)
Apr-06-23 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-23 09:01AM	Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome (Business Wire)
Mar-08-23 12:12PM	Q4 2022 Marinus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.33%
Mar-07-23 05:15PM	Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Mar-06-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +6.15%
Feb-15-23 01:00PM	The past five years for Marinus Pharmaceuticals (NASDAQ:MRNS) investors has not been profitable (Simply Wall St.)
10:24AM	Billionaire Steve Cohen Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
Feb-13-23 07:15AM	Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023 (Business Wire)
Feb-10-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-07-23 07:15AM	Marinus Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Jan-30-23 04:01PM	Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors (Business Wire)
Jan-20-23 02:17PM	Noting Strong Progress On Marinus Pharma's Lead Drug Ganaxolone, Analyst Initiates With 300% Upside (Benzinga) +8.45%
Jan-09-23 04:17PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.47%
Jan-05-23 04:01PM	Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update (Business Wire)
Dec-30-22 12:46AM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-21-22 07:20AM	Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) top owners are individual investors with 34% stake, while31% is held by institutions (Simply Wall St.) -5.12%
Dec-09-22 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Nov-30-22 04:01PM	Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting (Business Wire)
Nov-18-22 09:00AM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Nov-17-22 01:47PM	Marinus Pharmaceuticals signs collaboration deal worth up to $266M with Chinese biotech firm (American City Business Journals)
09:17AM	Marinus Pharma, Tenacia Biotech Ink Ganaxolone Agreement In China (Benzinga)
07:00AM	Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board (Business Wire)
07:00AM	Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China (Business Wire)
Nov-10-22 12:59PM	Marinus Pharmaceuticals expects to reel in $60M from stock, warrants sale (American City Business Journals)
07:34AM	Marinus Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-07-22 11:12PM	Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering (Business Wire)
05:15PM	Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:23PM	Marinus Pharmaceuticals Announces Proposed Public Offering (Business Wire)
04:00PM	Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results (Business Wire)

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Braunstein Scott	CHAIRMAN AND CEO	Mar 27 '24	Option Exercise	4.28	50,000	214,000	273,512	Mar 27 11:55 AM
Shafer Christina	CHIEF COMMERCIAL OFFICER	Feb 20 '24	Sale	9.56	2,153	20,583	60,308	Feb 22 04:05 PM
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Feb 20 '24	Sale	9.57	1,894	18,126	52,966	Feb 22 04:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Feb 16 '24	Sale	9.94	11,850	117,789	223,512	Feb 21 04:05 PM
Pfanstiel Steven	CFO AND COO	Feb 16 '24	Sale	9.97	3,092	30,827	71,697	Feb 21 04:05 PM
Hulihan Joseph	CHIEF MEDICAL OFFICER	Feb 16 '24	Sale	9.98	2,814	28,084	66,635	Feb 21 04:06 PM
Braunstein Scott	CHAIRMAN AND CEO	Aug 08 '23	Sale	8.94	30	268	160,762	Aug 08 09:05 PM
Pfanstiel Steven	CFO AND COO	Aug 08 '23	Sale	8.93	14	125	49,324	Aug 08 09:05 PM
Hulihan Joseph	CHIEF MEDICAL OFFICER	Aug 08 '23	Sale	8.93	13	116	47,614	Aug 08 09:05 PM
Shafer Christina	CHIEF COMMERCIAL OFFICER	Aug 08 '23	Sale	8.93	11	98	40,626	Aug 08 09:05 PM
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Aug 08 '23	Sale	8.93	11	98	33,025	Aug 08 09:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Aug 07 '23	Sale	9.55	6,413	61,244	160,792	Aug 08 09:05 PM
Hulihan Joseph	CHIEF MEDICAL OFFICER	Aug 07 '23	Sale	9.55	2,889	27,590	47,627	Aug 08 09:05 PM
Pfanstiel Steven	CFO AND COO	Aug 07 '23	Sale	9.54	2,790	26,617	49,338	Aug 08 09:05 PM
Shafer Christina	CHIEF COMMERCIAL OFFICER	Aug 07 '23	Sale	9.52	2,385	22,705	40,637	Aug 08 09:05 PM
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Aug 07 '23	Sale	9.54	2,169	20,692	33,036	Aug 08 09:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRNS

Marinus Pharmaceuticals Inc

Upgrade your FINVIZ experience